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Abstract 
 
Polycystic kidney disease is a genetic disorder characterized by growth of fluid-filled 
cysts predominately in kidney and liver. The only treatment currently available is the 
removal/aspiration of the largest cysts or organ transplantation.  Promising pharmaceutical 
agents in clinical trials interfere with the action of hormones that increase cAMP thereby 
inhibiting secretion of Cl-, and compensatory fluid flux, into the cysts. Other treatments proposed 
include chemotherapeutic and immunosuppressive drugs that interfere with cellular proliferation 
as well as with signaling pathways for Cl- secretion.  Long-term use of these agents will have 
multiple side effects.  Based on a recent observation that peroxisome proliferator activated 
receptor γ agonists such as Actos (pioglitazone) and Avandia (rosiglitazone) decrease mRNA 
levels of a Cl- transport protein and the Cl- secretory response to vasopressin stimulation in 
cultured renal cells, it is hypothesized that PPARγ agonists will inhibit cyst growth.  The current 
studies show that a 7 or 14 week feeding regimen of 20 mg/Kg BW pioglitazone inhibits renal 
and hepatic bile duct cyst growth in a rodent model orthologous to human PKD.  In addition, the 
degree of renal cortical fibrosis was diminished in the pioglitazone-treated animals after 14 
weeks.  These results suggest that PPARγ agonists may be effective in controlling both renal and 
hepatic cyst growth and renal fibrotic development in polycystic kidney disease. 
